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Nonalcoholic fatty liver disease (NAFLD) is a major cause of chronic liver disease, 
which affects roughly 26% of US population - about 80 million Americans.1 It is estimated that 
20-30% of NAFLD population may develop nonalcoholic steatohepatitis (NASH), which is
considered a leading cause of end-stage liver disease, hepatocellular carcinoma and liver 
transplantation.2 Since obesity and type 2 diabetes mellitus (T2DM) prevalence are expected to 
increase in the upcoming years, studies project a significant increase in NAFLD-related 
morbidity and mortality in the United States.1, 3 The fibrosis stage is a major determinant not 
only of long-term liver-related outcomes and mortality, but also has been associated with 
increased risk of cardiovascular events and cancers. Thus, pharmacological therapies targeting 
fibrosis pathways are ideal candidates to prevent or reduce fibrosis progression and subsequently 
disease burden.4  Despite the rapidly growing burden of NAFLD/NASH, medical strategies to 
ameliorate fibrosis including lifestyle or pharmacological interventions are effective only in a 
limited number of patients.2, 5  
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It is estimated that tens of millions of adults regularly take aspirin in the US. Low-dose 
regular aspirin use has shown excellent benefits in reducing the risk of heart/stroke attacks and 
gastrointestinal cancers in selected high-risk adults who are not at increased risk for bleeding.6, 7 
New experimental and clinical evidence is now emerging that the drug may help to curb liver 
and cardiac8 fibrosis as well as reduce risk of hepatocellular carcinoma.9, 10  
In the present issue of Clinical Gastroenterology and Hepatology, Simon et al11 
examined the relationship between regular use of aspirin and the risk of fibrosis in adults with 
biopsy proven NAFLD. A primary cross-sectional analysis determined the prevalence of fibrosis 
on liver histology in 361 NAFLD patients, and two secondary longitudinal analyses further 
explored the cumulative incidence of advanced fibrosis (F3-4) as determined by serum 
biomarkers (n=317) or liver histology (n=72) among individuals with early stages of fibrosis 
(F0-2) at enrollment biopsy. Covariate-adjusted multivariable models were constructed including 
well-recognized confounders, and aspirin use was modeled as a time-varying covariate to 
overcome the immortal time bias. A total of 151 patients were identified as regular users of 
aspirin and were compared to 210 non-regular users. Both cross-sectional and longitudinal 
analyses showed independent and negative associations between fibrosis severity and daily 
aspirin use. In the cross-sectional analysis, regular use of aspirin lowered the risk of fibrosis (adj. 
OR: 0.54, 95% CI: 0.31-0.82) even after controlling by concurrent use of non-aspirin NSAIDs 
and other confounders. The longitudinal analysis also showed that daily aspirin use was 
associated with significantly lower incidence of advanced fibrosis (adj. HR: 0.63, 95% CI 0.43-
0.85). To authenticate this finding, researchers also examined the risk of disease progression 
among patients with paired liver biopsies. This subgroup analysis showed that risk of advanced 
fibrosis remained consistently lower among daily aspirin users (adj. HR: 0.64, 95% CI 0.50-0.80) 
than non-users. The researchers further tested if the association between pre- and post-enrollment 
aspirin use and lower risk of fibrosis could be exposure duration-dependent, and found that 
longer aspirin consumption was associated lower risk of fibrosis progression, and at least 2 years 
of regular aspirin use was required to detect beneficial effects.  These provocative observations 
are of potential clinical utility.  
Chronic inflammation is a known risk factor for liver disease progression or cancer, 
especially in patients who suffer from chronic inflammatory processes such as chronic viral 
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hepatitis, NAFLD or inflammatory bowel disease. In recent years, preclinical models of chronic 
liver disease have suggested that platelets play a central role in liver inflammation and fibrosis.12 
Thus, a dual anti-platelet and anti-inflammatory function of low-dose aspirin (81-325 mg) may 
provide foundational pathophysiological basis to explain its antifibrotic and chemopreventative 
benefits. Aspirin modulates cyclooxygenase-2 (COX-2), a key enzyme that induces pro-
inflammatory prostaglandins, including prostaglandin E2 which increases cellular proliferation, 
promotes angiogenesis, and increases resistance to apoptosis.13 In addition, aspirin also inhibits 
cyclooxygenase-1 (COX-1) expression which controls prostaglandin levels involved in platelet 
activation and protection of gastrointestinal mucosa. These effects, along with other non-COX 
mechanisms affecting the expression of other inflammatory and pro-tumoral molecules, may 
explain the dramatic effect of aspirin on liver fibrosis progression or cancer rates. Figure 1 
illustrates physiologic mechanisms to explain potential antifibrotic and chemopreventative 
effects of aspirin.   
Consistent with RCTs and other observational studies, long-term use of low-dose aspirin 
is associated with a dramatic reduction in the incidence of heart attack, stroke and 
gastrointestinal and liver cancers.9, 14 However, heart- and cancer-related benefits of aspirin are 
offset by the risk for serious bleeding events. Even at low or very low doses, aspirin has shown a 
59% increased risk of major gastrointestinal bleeding and 33% increased risk of hemorrhagic 
stroke, particularly in patients at high risk, including those with prior GI bleeding or ulceration, 
prior complications from aspirin use, or known bleeding diathesis.15 These findings prompted the 
US Preventive Services Task Force to recommend aspirin use only in adults aged between 50-69 
years with determined cardiovascular risk profile to prevent colorectal cancer.14  
While current study provides provocative data supporting and extending the currently 
available literature, there are important clinical and methodologic limitations that deserve further 
discussion. First, major bleeding rates were not reported among aspirin users vs. non-users. It is 
particularly important as these events have a notable influence on acceptability and adherence 
during long-term aspirin use. Second, the optimum antifibrotic dose of aspirin remains in doubt. 
Third, benefits and harms of prophylactic use of aspirin among patients with high burden disease 
such as cirrhosis, type 2 diabetes and age ≥ 70 years are unknown. Fourth, although authors 
showed the beneficial effect of daily aspirin use on fibrosis progression was unchanged after 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
controlling by other medications with recognized disease-modifying effects such as metformin,16 
vitamin E,17, 18 pioglitazone18 and statins, drug-drug additive and interaction effects were not 
explored. Finally, the present study lacked detailed information regarding non-aspirin NSAIDs 
dosage and duration, and the use of other anti-platelet drugs which highlight the need for further 
studies exploring the impact of these medications alone or in combination with aspirin for 
prevention of fibrosis.  
The present study provides further clinical support to the emerging evidence for a critical 
pathological link between platelet activation, pro-inflammatory environment and liver fibrosis 
and hepatocellular carcinoma. While certainly promising, aspirin use to improve liver fibrosis or 
liver outcomes in NAFLD is not ready for prime time in clinical practice.  Further high-quality 
cohort studies as well as randomized controlled studies are required to explore the beneficial 
effects of aspirin or even other anti-platelets or non-aspirin NSAIDs in preventing hepatic 
fibrosis and its impact on long-term clinical outcomes among NAFLD patients. Even if multiple 
other studies show benefits for daily aspirin use, considering that patients with NAFLD cirrhosis 
are at higher risk for bleeding complications, one needs to carefully consider which NAFLD 
subpopulation derive the most benefit from daily aspirin use.    
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FIGURE LEGEND 
Figure 1. Mechanisms of action of aspirin.  
Aspirin in low doses (81-325 mg/day) irreversibly inhibits platelet TXA2 synthesis, however, 
high doses (2-3 g/day) are required to inhibit formation of PGI2. High doses irreversibly 
inactivate both isoforms of the COX enzymes (COX-1 and COX-2). The gastrointestinal adverse 
effects of aspirin and nonsteroidal anti-inflammatory drugs are mainly a result of COX-1 
inhibition. Aspirin has been found to inhibit IκB kinase β and prevent NF-κB activation. 
Inhibition of both pathways may affect the transcription of several proteins involved in 
inflammatory responses and angiogenesis which may contribute to the observed antifibrotic and 
anticancer effects.   
Abbreviations: PGG2, prostaglandin G2; COX, cyclooxygenase; PGH2, prostaglandin H2; 
TXA2, thromboxane A2; PGE2, prostaglandin E2; PGI2, prostaglandin I2; IL, interleukin; NF-
kB, nuclear factor kappa B.      
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